Pharmaceutical Firms Seek More 340B Program Oversight

Manufacturers are looking for increased transparency in drug distribution to prevent duplicate commercial rebates.

Updated on Oct. 20, 2026 in Healthcare

Isometric editorial illustration of pharmaceutical ampoules arranged in a modular grid, representing drug distribution transparency. — Pharmaceutical manufacturers are advocating for enhanced oversight of the 340B drug pricing program to mitigate risks associated with duplicate commercial rebates. AI Illustration. Upload story photo >

Live Poll

Do you trust that current pharmaceutical pricing programs effectively balance patient access with fair market costs?

Pharmaceutical manufacturers are pushing for better visibility into the 340B Drug Pricing Program to prevent illegal duplicate discounts. Companies are seeking to curb commercial rebate exposure that occurs when 340B pricing and commercial claims overlap.

Why it matters

The lack of clear statutes regarding commercial-side duplicate discounts creates financial uncertainty for drug makers. Ensuring compliance helps manufacturers protect profitability as 340B volume grows over time.

Large pharmaceutical companies pay an 8% wholesaler distribution fee, while some firms report potential cost savings of half on those fees through alternative supply chain strategies.

The players

340B ESP

This organization provides data services designed to increase manufacturer visibility into 340B drug distribution processes.

RxParadigm

This company offers data solutions to help pharmaceutical manufacturers manage distribution transparency.

Kalderos

This firm provides data analytics and software tools aimed at preventing discount leakage and ensuring 340B program compliance.

Direct Customer Solutions

This entity assists manufacturers by providing distribution data and facilitating access to alternative drug supply chains.

The details

Manufacturers are working with data providers like 340B ESP, RxParadigm, and Kalderos to gain visibility into distribution chains. Small pharmaceutical companies, which often lack the leverage to negotiate favorable wholesaler terms, are particularly vulnerable as 340B volume increases.

Post-launch drug pricing can be negatively impacted by 340B volume and commercial rebates.
The majority of a drug's unit sales may fall under 340B pricing within five years of launch.

Market Landscape

Manufacturers are attempting to stabilize margins in a market where 340B volume is projected to account for the majority of unit sales within five years of a product launch. This push for transparency pits pharmaceutical companies against long-standing wholesaler distribution models.

While these administrative shifts focus on manufacturer-wholesaler relationships, changes in distribution efficiency may eventually influence the broader pricing structure of prescription drugs. Consumers should monitor how these efforts impact the availability and cost of specialty medications.

The takeaway

Manufacturers are increasingly reliant on third-party data firms to monitor the complex intersection of federal drug discounts and commercial rebates. Companies must strategically manage their distribution chains early in a product's lifecycle to avoid long-term margin erosion.